AstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs … – Clinical Leader

Clinical LeaderAstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs …Clinical LeaderCarlsbad, CA /PRNewswire/ – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds …AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense DrugsPress ExaminerAstraZeneca, Isis partner to discover and develop new antisense drugsPharmaceutical Business ReviewAstraZeneca, Isis Pharma Join To Discover And Develop Antisense DrugsGuide2NigeriaDispatch Timesall 40 news articles »

Read More

Isis Pharma (ISIS), AstraZeneca (AZN) Enter Antisense Therapy Development … – StreetInsider.com

Guide2NigeriaIsis Pharma (ISIS), AstraZeneca (AZN) Enter Antisense Therapy Development …StreetInsider.comIsis Pharma (NASDAQ: ISIS) and AstraZeneca (NYSE: AZN) announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship …AstraZeneca, Isis Pharma Expand Antisense CollaborationGenetic Engineering & Biotechnology NewsAstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs …PR Newswire (press release)Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for …News-Medical.netPMLiVE -Nasdaqall 40 news articles »

Read More

AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs … – PR Newswire (press release)

Guide2NigeriaAstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs …PR Newswire (press release)CARLSBAD, Calif., Aug. 3, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new …Isis Pharma (ISIS), AstraZeneca (AZN) Enter Antisense Therapy Development …StreetInsider.comAstraZeneca, Isis Pharma Expand Antisense CollaborationGenetic Engineering & Biotechnology NewsIsis Pharmaceuticals, AstraZeneca to develop antisense therapies for …News-Medical.netPMLiVEall 40 news articles »

Read More

Novel Antisense Inhibitors May Lower Triglyceride, Lipoprotein(a) Levels – Medscape

Novel Antisense Inhibitors May Lower Triglyceride, Lipoprotein(a) LevelsMedscapeBOSTON, MA and LONDON, UK — Novel “antisense” drugs may be effective in targeting different apolipoproteins in patients with dyslipidemia, suggest two early studies. The first report, published in the July 30, 2015 issue of the New England Journal of …New Antisense APOC3 Inhibitor Can Decrease TriglyceridesEndocrinology Advisorall 4 news articles »

Read More

Study finds benefits of antisense therapy targeting apolipoprotein(a) – Pharmacy Today, American Pharmacists Association, pharmacist.com

Study finds benefits of antisense therapy targeting apolipoprotein(a)Pharmacy Today, American Pharmacists Association, pharmacist.comA recent study investigated the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx. The drug is a second-generation antisense drug that reduces the synthesis of apolipoprotein(a) (apo[a]) in the liver, which is a risk factor for …

Read More

Study finds benefits of antisense therapy targeting apolipoprotein(a) – Pharmacy Today, American Pharmacists Association, pharmacist.com

Study finds benefits of antisense therapy targeting apolipoprotein(a)Pharmacy Today, American Pharmacists Association, pharmacist.comA recent study investigated the safety, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx. The drug is a second-generation antisense drug that reduces the synthesis of apolipoprotein(a) (apo[a]) in the liver, which is a risk factor for …

Read More

Antisense and RNAi Therapeutics Market 2015 reviews, research, trends and … – Medgadget.com (blog)

Medgadget.com (blog)Antisense and RNAi Therapeutics Market 2015 reviews, research, trends and …Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015-2019Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which …and more »

Read More

Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The … – PR Newswire (press release)

Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The …PR Newswire (press release)Once engaged, the RNAi mechanism removes the ‘sense’ strand of the dsRNA leaving a functional ‘antisense’ single-stranded RNA to bind to the target mRNA and cause degradation. In these studies, Isis scientists and collaborators demonstrated that …and more »

Read More